About Metagen Therapeutics
Metagen Therapeutics is a company based in Tokyo (Japan) founded in 2020 by Shinji Fukuda, Takuji Yamada, Masatsugu Fukuda, Taku Nakahara, and Dai Ishikawa. Metagen Therapeutics has raised $35.46 million across 8 funding rounds from investors including Keio Innovation Initiative, JAFCO and JIC Venture Growth Investments. Metagen Therapeutics operates in a competitive market with competitors including Medeloop, Pure Biologics, Hyku Biosciences, Sirion Biotech and Taizhou Baiying Biotechnology, among others.
- Headquarter Tokyo, Japan
- Founders Shinji Fukuda, Takuji Yamada, Masatsugu Fukuda, Taku Nakahara, Dai Ishikawa
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$35.46 M (USD)
in 8 rounds
-
Latest Funding Round
$7.62 M (USD), Series B
Feb 26, 2026
-
Investors
Keio Innovation Initiative
& 20 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Metagen Therapeutics
Metagen Therapeutics has successfully raised a total of $35.46M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $7.62 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Metagen Therapeutics
Metagen Therapeutics has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Keio Innovation Initiative, JAFCO and JIC Venture Growth Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on growth stage companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in Japanese tech and life sciences are made.
|
Locked | Locked | Locked |
Investor details for Metagen Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Metagen Therapeutics
Investment portfolio details for Metagen Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Metagen Therapeutics
Detailed financials for Metagen Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Metagen Therapeutics Comparisons
Peer comparison for Metagen Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Metagen Therapeutics
Metagen Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Medeloop, Pure Biologics, Hyku Biosciences, Sirion Biotech and Taizhou Baiying Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery services are offered by Medeloop as a CRO.
|
|
| Locked | Locked | Locked |
Specialized CRO with expertise in recombinant protein production and purification
|
|
| Locked | Locked | Locked |
Covalent medicines platform is advanced for drug discovery targeting proteins.
|
|
| Locked | Locked | Locked |
Customized AAV-based viral vectors for gene therapy are supplied.
|
|
| Locked | Locked | Locked |
Antibody-drug research and development services are provided.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to pharmaceutical and biotech clients.
|
Detailed competitors of Metagen Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Metagen Therapeutics
Complete news archive for Metagen Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Metagen Therapeutics
Metagen Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Metagen Therapeutics is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Taku Nakahara is the current CEO of Metagen Therapeutics. They have also founded this company.
Metagen Therapeutics is a funded company, having raised a total of $35.46M across 8 funding rounds to date.
Metagen Therapeutics was established in 2020 in Tokyo, Japan, as a contract research organization (CRO) specializing in the microbiome sector. Drug discovery and development services for microbiome-based therapeutics are delivered to clients in the pharmaceutical industry. Operations center on advanced research methodologies to identify and validate microbial targets. The companys activities support early-stage to preclinical pipeline advancement, with a focus on therapeutic applications in human health.
Metagen Therapeutics's top competitors include Medeloop, Pure Biologics and Centivax.
Metagen Therapeutics has 21 investors. Key investors include Keio Innovation Initiative, JAFCO, JIC Venture Growth Investments, JAFCO Group, and FTI.